EFFECT OF EZETIMIBE ON LIPOPROTEIN SUBFRACTION CONCENTRATIONS: THE ROLE OF ATORVASTATIN PRETREATMENT

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

M A Austin, Mary‐Claire King, K M Vranizan et al. · Circulation · 1990 · 1.4K citations · Full text

Genetics, Nuclear Families, Genetic Epidemiology +20

Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol

Margaret E. Brousseau, Ernst J. Schaefer, Megan L. Wolfe et al. · New England Journal of Medicine · 2004 · 774 citations · Full text

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

Margarita García‐Calvo, JeanMarie Lisnock, Herbert G. Bull et al. · Proceedings of the National Academy of Sciences · 2005 · 759 citations · Full text

Biochemistry, Medicine, Niemann-pick C1-like 1 +9

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

Alan Chait, Ronald Brazg, Diane L. Tribble et al. · The American Journal of Medicine · 1993 · 554 citations

Metabolic Syndrome, Pattern B, Cardiovascular Disease +14

Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

James D. Otvos, Dorothea Collins, David S. Freedman et al. · Circulation · 2006 · 550 citations · Full text